Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®

  title={Content of Botulinum Neurotoxin in Botox{\textregistered}/Vistabel{\textregistered}, Dysport{\textregistered}/Azzalure{\textregistered}, and Xeomin{\textregistered}/Bocouture{\textregistered}},
  author={J{\"u}rgen Frevert},
  journal={Drugs in R\&D},
  pages={67 - 73}
  • J. Frevert
  • Published 1 July 2010
  • Medicine, Biology
  • Drugs in R&D
AbstractBackground: Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. [] Key MethodMethods: Rabbit and guinea pig antibodies raised against the 150kD BoNT/A neurotoxin purified from Clostridium botulinum type A, strain ATCC 3502 (‘Hall strain’), were used in a…
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
The available clinical and preclinical data suggest that a conversion ratio ABO:ONA of 3:1—or even lower—could be appropriate for treating spasticity, cervical dystonia, and blepharospasm or hemifacial spasm.
AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients
Higher amounts of active neurotoxin are injected with Dysport®, at FDA-approved doses, than with other products, which might explain the long duration of action reported across multiple indications, which benefits patients, caregivers, clinicians, and healthcare systems.
IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A
The role of unnecessary clostridial proteins in BoNT-A is reviewed and the unique incobotulinumtoxinA manufacturing and purification process is discussed with a focus on the implications for use in aesthetic medicine.
Rare Complication of Botox Injection: A Case Report
The patient was a 22 years old man who received Botox for axillary hyperhidrosis after two weeks, when most of generalized complications of botulinum toxin appeared, and this case was introduced for being aware of dangerous complication of Botox.
Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.
It is important for clinicians to have all three BoNTAs available in order to choose the most suitable preparation for the specific indication in the single patient.
Comparison of botulinum neurotoxin type A formulations in Asia
Xeomin, which has 416 pg/vial of purified neurotoxin and 0.240 U of efficacy per pg of neurotoxin, has the lowest neurotoxin protein content and consequently the highest specific potency compared to the four Asian BoNT/A preparations in this study.
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A
DaxibotulinumtoxinA for Injection (DAXI) is a novel BoNTA product containing highly purified 150-kDa core neurotoxin and is the first to be formulated with a proprietary stabilizing excipient peptide (RTP004) instead of human serum albumin.
Is it Possible to Accurately Determine Content of Botulinum Neurotoxin Type A in Drug Products?
It is claimed that antibodies have no ability to detect additional complexing proteins/other clostridial proteins that are known to be present in products other than Xeomin® but no direct evidence of this specificity is directly presented in this paper.


Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
NT 201 was effective, well tolerated and non-inferior to BOT in the treatment of both CD and BEB and there were no differences between the two therapies in terms of onset of action, duration and waning of effect.
Botulinum toxin in the treatment of OAB, BPH, and IC.
  • Christopher P. Smith
  • Medicine
    Toxicon : official journal of the International Society on Toxinology
  • 2009
Evidence for effectiveness of botulinum toxin for hyperhidrosis
There is a strong evidence to support the efficacy of botulinum toxin type A in axillary (Level A evidence) and palmar (Level B evidence) hyperhidrosis.
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
The data show that NT 201* is an effective and safe treatment for patients suffering from blepharospasm.
Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose‐conversion factors are not applicable.
Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations.
Properties and use of botulinum toxin and other microbial neurotoxins in medicine.
Crystalline botulinum toxin type A was licensed in December 1989 by the Food and Drug Administration for treatment of certain spasmodic muscle disorders following 10 or more years of experimental treatment on human volunteers and its chemical, physical, and biological properties as applied to its use in medicine are described.
Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use
SummaryThe neurotoxins produced byClostridium botulinum are the most potent acute toxins known and are the causative agents of the neuroparalytic disease botulism. The toxins act primarily at
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
A new botulinum toxin type A free of complexing proteins (NT 201) was compared with BOTOX in patients with cervical dystonia by means of a double-blind noninferiority trial and shows that NT 201 is at least as effective and safe as BotoX.